Policy | May 29, 2021
Shilpa Medicare Jadcherla facility gets GMP certification from Russia
The GMP certificate is valid for three years until April 2024.
The GMP certificate is valid for three years until April 2024.
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
Availability of drugs is being monitored by implementing a three-pronged strategy of supply chain management, demand side management, and affordability.
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
The agreement will help ensure wider reach and access to patients in India
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
Much-needed diagnostics supplies will help accelerate testing capabilities of hospitals and clinics across India
Subscribe To Our Newsletter & Stay Updated
